Allarity's $20M Lifeline Fuels Novel Cancer Drug Toward FDA Approval

TARPON SPRINGS, FL – March 06, 2026 – Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced today it has closed a $20 million non-convertible debt financing with private investment firm Streeterville Capital. The deal provides a critical injection of capital expected to extend the company’s cash runway into the summer of 2028 and accelerate the development of its lead drug candidate, stenoparib, for advanced ovarian cancer.

The financing is structured as a note purchase agreement, providing approximately $20 million in net proceeds. These funds are designated to propel stenoparib through the completion of its ongoing Phase 2 clinical trial, support preparations for pivotal studies and an end-of-Phase-2 meeting with the U.S. Food and Drug Administration (FDA), and advance the company's proprietary companion diagnostic platform.

A Strategic Lifeline in a Challenging Market

For clinical-stage biotechnology firms like Allarity, which operate without product revenue and face high research and development costs, securing funding is a constant and critical challenge. Prior to this financing, the company reported a net loss of $7.9 million for the first three quarters of 2025 and an operating cash outflow of $11.6 million, giving it a cash runway of just over a year. This $20 million infusion serves as a vital lifeline, significantly de-risking the company's immediate financial future and providing the stability needed to pursue key clinical and regulatory milestones.

The decision to use non-convertible debt is particularly noteworthy. In a market where a company's stock has seen a significant decline—Allarity’s shares fell by 48% in the six months preceding the announcement—raising capital through equity can be highly dilutive to existing shareholders. By opting for debt that does not convert to stock, Allarity has secured necessary funds while protecting its current investors from further dilution.

Details from the company’s Form 8-K filing with the Securities and Exchange Commission reveal a carefully structured deal. The financing consists of two promissory notes: a $10.93 million unsecured note with a 9% interest rate and a $10 million secured note with a 5% interest rate, both maturing in 18 months. The agreement includes stringent covenants that restrict Allarity’s ability to take on new debt or issue certain types of securities, along with protective clauses for the lender. This structure underscores both the high-stakes nature of the investment and Streeterville Capital’s confidence in the company's potential to meet its obligations.

Advancing a Differentiated Attack on Ovarian Cancer

The primary focus of the new funding is stenoparib, a novel, dual-action inhibitor designed to treat advanced ovarian cancer. Unlike first-generation PARP inhibitors, which target a single DNA repair pathway, stenoparib also inhibits tankyrase enzymes, which play a key role in the WNT signaling pathway. Aberrant WNT signaling is implicated in the growth and progression of numerous cancers, making this dual-inhibition mechanism a promising and differentiated therapeutic strategy.

This distinction is especially relevant in an oncology landscape where several earlier PARP inhibitors were withdrawn from the market for later-line ovarian cancer treatment after failing to demonstrate a significant long-term survival benefit. Stenoparib aims to succeed where others have fallen short, offering a new option for heavily pre-treated patients, including those with platinum-resistant disease who have exhausted other therapies.

Recent clinical data has bolstered confidence in the drug's potential. During a presentation at the AACR Special Conference on Ovarian Cancer in September 2025, Allarity reported that its Phase 2 trial showed stenoparib provided durable clinical benefit. The median overall survival for a subset of patients had not yet been reached but was already exceeding 25 months, with one patient remaining on therapy for over two years. Crucially, this benefit was observed in patients regardless of their BRCA mutation status, potentially expanding the drug’s applicability beyond the patient populations served by traditional PARP inhibitors. Stenoparib has also demonstrated a favorable safety profile, with significantly less bone marrow toxicity.

“This financing demonstrates the confidence which Streeterville has in Allarity and the capital received positions us to complete Phase 2 enrollment, prepare for our FDA meeting, advance our companion diagnostic strategy, and prepare for pivotal development of stenoparib in advanced ovarian cancer,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “We view stenoparib as a novel, highly differentiated therapeutic candidate, and this non-convertible financing provides the resources necessary to propel its continued advancement.”

The Power of Prediction: The DRP® Platform

Central to Allarity’s entire clinical strategy is its proprietary Drug Response Predictor (DRP®) companion diagnostic platform. The company's mission is not just to develop new cancer drugs, but to ensure they are given to the patients most likely to benefit. The DRP® platform is the tool designed to achieve that goal.

By analyzing the messenger RNA (mRNA) expression profile from a patient’s tumor biopsy, the DRP® platform generates a score that predicts the likelihood of response to a specific drug. In the stenoparib trial, patients selected using a high DRP® score demonstrated markedly better outcomes, validating the platform's potential to enhance therapeutic efficacy. This personalized approach aims to improve patient outcomes while avoiding the costs and toxicities of ineffective treatments.

This strategy aligns perfectly with the broader industry-wide shift toward precision medicine. The recent FDA approval of immunotherapy drugs like Keytruda for biomarker-defined subsets of ovarian cancer patients highlights the growing regulatory and clinical acceptance of targeted treatments. With the new funding, Allarity plans to further advance its DRP® companion diagnostic for stenoparib, aiming for parallel regulatory review with the drug itself.

Investor Confidence and Market Realities

The financing partner, Streeterville Capital, is a Utah-based venture firm that specializes in providing growth capital to companies through structured finance arrangements. Its investment in Allarity is consistent with its strategy of funding growth-stage companies with significant capital requirements but promising technology.

The market’s initial reaction to the news was cautiously optimistic, with Allarity's stock (ALLR) seeing a modest increase of nearly 3% in trading following the announcement. However, broader analyst sentiment remains divided. While one firm holds a “Strong Buy” rating and an ambitious $9.50 price target based on stenoparib's clinical promise, other analyses from TipRanks and MarketBeat reflect more caution, citing weak financial metrics and assigning “Hold” or “Underperform” ratings.

This divergence captures the essential tension of investing in clinical-stage biotech. The science behind stenoparib and the DRP® platform presents a compelling case for a potential breakthrough in a high-need area of oncology. At the same time, the company's financial history, ongoing cash burn, and the restrictive terms of the new debt highlight the substantial risks inherent in the long journey from lab to market. This $20 million financing provides a crucial bridge over perilous waters, but the path to regulatory approval and commercial success remains both promising and challenging.